- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sitagliptin with basal-plus insulin regimen more effective than insulin therapy alone for type 2 diabetes: Study
Mexico: SITA-PLUS hospital trial published in the Journal of Diabetes and its Complications has shed light on the safety and efficacy of sitagliptin with basal-plus (BP) insulin regimen versus insulin alone in non-critically hospitalized patients with type 2 diabetes (T2D).The study revealed that the sitagliptin and BP regimen combination is safe and more effective than insulin therapy alone...
Mexico: SITA-PLUS hospital trial published in the Journal of Diabetes and its Complications has shed light on the safety and efficacy of sitagliptin with basal-plus (BP) insulin regimen versus insulin alone in non-critically hospitalized patients with type 2 diabetes (T2D).
The study revealed that the sitagliptin and BP regimen combination is safe and more effective than insulin therapy alone for inpatients with type 2 diabetes and hyperglycemia.
"Combining sitagliptin with a basal-plus insulin regimen leads to a comparable risk of hypoglycemia, lower daily blood glucose levels, and lower insulin doses than the basal-plus regimen alone," the researchers reported.
The recommended method for insulin administration is a basal-bolus regimen, which involves the daily subcutaneous injection of basal insulin, along with rapid-acting insulin before meals for prandial and correctional doses. However, its application is limited by the complexity of this approach and the risk of hypoglycemia.
Previous studies have revealed that basal and correctional insulin doses (basal-plus regimen) with sitagliptin are similar to the basal-bolus insulin regimen in hyperglycemia management in a hospital setting. However, no clarity exists on whether this combination is better than a basal-plus regimen alone. Therefore, Abraham Edgar Gracia-Ramos, Instituto Mexicano del Seguro Social, Mexico City, Mexico, and colleagues aimed to compare the safety and efficacy of basal-plus insulin regimen with or without sitagliptin in non-critically ill patients with type 2 diabetes.
For this purpose, the researchers conducted an open-label, randomized clinical trial comprising patients with a previous diagnosis of T2D and blood glucose (BG) between 180 and 400 mg/dL. Participants received basal and correctional insulin doses (BP regimen) either with or without sitagliptin. The study's primary outcome was the difference in the mean daily blood glucose among the groups. Seventy-six patients (mean age 60 years, 64 % men) were randomized.
Based on the study, the researchers reported the following findings:
- Compared with BP insulin therapy alone, the sitagliptin-BP combination led to a lower mean daily BG (158.8 versus 175.0 mg/dL), a higher percentage of readings within a BG range of 70–180 mg/dL (75.9 % versus 64.7 %), and a lower number of BG readings >180 mg/dL.
- Sitagliptin-BP resulted in fewer basal and supplementary insulin doses and lower daily insulin injections than those with insulin alone.
- The proportion of patients with hypoglycemia was similar in the two groups.
"These results are significant because using DPP-4 inhibitors with basal-plus insulin therapy simplifies hospital diabetes management for healthcare professionals, improves treatment adherence, and leads to better patient outcomes," the researchers wrote.
Reference:
Gracia-Ramos, A. E., Cruz-Dominguez, M. D. P., Madrigal-Santillán, E. O., Rojas-Martínez, R., Morales-González, J. A., Morales-González, Á., Hernández-Espinoza, M., Vargas-Peñafiel, J., & Tapia-González, M. D. L. Á. (2024). Efficacy and safety of sitagliptin with basal-plus insulin regimen versus insulin alone in non-critically ill hospitalized patients with type 2 diabetes: SITA-PLUS hospital trial. Journal of Diabetes and its Complications, 38(5), 108742. https://doi.org/10.1016/j.jdiacomp.2024.108742
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751